Lipocine (LPCN) shares soared 5.5% in the last trading session to close at $10. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.2% gain over the past four weeks.Lipocine’s stock price gain can be attributed to increasing investor confidence in recent pipeline developments of its investigational drug LPCN 1154 (oral brexanolone) for the treatment of postpartum depression. The company is evaluating the candidate in phase III stud ...

Carter's (CRI) came out with quarterly earnings of $1.9 per share, beating the Zacks Consensus Estimate of $1.7 per share. This compares to earnings of $2.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +12.09%. A quarter ago, it was expected that this maker of children's apparel and accessories would post earnings of $0.78 per share when it actually produced earnings of $0.74, delivering a surprise of -5.13%.Over the last ...

Core Viewpoint - Amneal Pharmaceuticals reported quarterly earnings of $0.21 per share, exceeding the Zacks Consensus Estimate of $0.18 per share, and showing an increase from $0.12 per share a year ago, resulting in an earnings surprise of +18.85% [1] Financial Performance - The company achieved revenues of $814.32 million for the quarter ended December 2025, which was slightly below the Zacks Consensus Estimate by 0.19%, but an increase from $730.52 million year-over-year [2] - Over the last four quarters, Amneal has surpassed consensus EPS estimates four times, but has only topped consensus revenue estimates once [2] Stock Performance - Amneal shares have increased approximately 15% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.9% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.22 on revenues of $753.87 million, and for the current fiscal year, it is $0.96 on revenues of $3.21 billion [7] - The estimate revisions trend for Amneal was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which Amneal belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, suggesting that the overall industry outlook may impact stock performance [8]

Golden Entertainment (GDEN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.11. This compares to earnings of $0.1 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -109.09%. A quarter ago, it was expected that this gaming services provider would post a loss of $0.08 per share when it actually produced a loss of $0.18, delivering a surprise of -125%.Over the last four quarters, the comp ...

Core Viewpoint - Applied Optoelectronics reported a quarterly loss of $0.01 per share, outperforming the Zacks Consensus Estimate of a loss of $0.12, indicating a significant earnings surprise of +91.89% [1][2] Financial Performance - The company posted revenues of $134.27 million for the quarter ended December 2025, slightly missing the Zacks Consensus Estimate by 0.05%, compared to revenues of $100.27 million a year ago [3] - Over the last four quarters, the company has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [2][3] Stock Performance - Applied Optoelectronics shares have increased approximately 66.7% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.5% [4] - The current Zacks Rank for the stock is 3 (Hold), indicating expected performance in line with the market in the near future [7] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $145.37 million, and for the current fiscal year, it is $0.55 on revenues of $761.96 million [8] - The trend of estimate revisions for the company was mixed ahead of the earnings release, which could change following the recent report [7] Industry Context - The Electronics - Semiconductors industry, to which Applied Optoelectronics belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [9]

分组1 - Ambarella reported quarterly earnings of $0.13 per share, exceeding the Zacks Consensus Estimate of $0.10 per share, and showing an increase from $0.11 per share a year ago, resulting in an earnings surprise of +30.00% [1] - The company achieved revenues of $100.87 million for the quarter ended January 2026, surpassing the Zacks Consensus Estimate by 0.56% and increasing from $84.01 million year-over-year [2] - Ambarella has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed the market, losing about 0.8% since the beginning of the year compared to the S&P 500's gain of 1.5% [3] - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $96.16 million, and for the current fiscal year, it is $0.64 on revenues of $431.43 million [7] - The Electronics - Semiconductors industry, to which Ambarella belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Core Viewpoint - Arcosa (ACA) reported quarterly earnings of $1.15 per share, exceeding the Zacks Consensus Estimate of $0.95 per share, and showing significant growth from $0.46 per share a year ago [1] Financial Performance - The earnings surprise for the quarter was +21.05%, with the company having surpassed consensus EPS estimates in all four of the last quarters [2] - Arcosa's revenues for the quarter reached $716.7 million, surpassing the Zacks Consensus Estimate by 0.38%, and up from $666.2 million year-over-year [3] Stock Performance - Arcosa shares have increased approximately 19.1% since the beginning of the year, compared to a 1.5% gain in the S&P 500 [4] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $0.51 for the upcoming quarter and $4.63 for the current fiscal year [8] - The Zacks Rank for Arcosa is currently 4 (Sell), indicating expected underperformance in the near future due to unfavorable estimate revisions prior to the earnings report [7] Industry Context - The Building Products - Miscellaneous industry, to which Arcosa belongs, is currently ranked in the bottom 30% of over 250 Zacks industries, suggesting potential challenges ahead [9]

Fox Factory Holding (FOXF) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +42.86%. A quarter ago, it was expected that this vehicle suspension maker would post earnings of $0.56 per share when it actually produced earnings of $0.23, delivering a surprise of -58.93%.Over the last four ...

NCR Atleos (NATL) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.32 per share. This compares to earnings of $1.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +12.88%. A quarter ago, it was expected that this provider of ATM services would post earnings of $1.01 per share when it actually produced earnings of $1.09, delivering a surprise of +7.92%.Over the last four quarters, ...

OPKO Health (OPK) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +39.39%. A quarter ago, it was expected that this holding company with investments in pharmaceutical and diagnostics companies would post a loss of $0.02 per share when it actually produced earnings of $0.03, delivering a s ...